501 Canal Boulevard
About Sangamo Therapeutics
Sangamo Therapeutics is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has open Phase 1/2 clinical trials in Hemophilia A and Hemophilia B, and lysosomal storage disorders MPS I and MPS II. Sangamo has an exclusive, global collaboration and license agreement with Pfizer Inc. for gene therapy programs for Hemophilia A, with Bioverativ Inc. for hemoglobinopathies, including beta thalassemia and sickle cell disease, and with Shire International GmbH to develop therapeutics for Huntington's disease. In addition, it has established strategic partnerships with companies in non-therapeutic applications of its technology, including Sigma-Aldrich Corporation and Dow AgroSciences.
508 articles with Sangamo Therapeutics
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported second quarter 2019 financial results and recent business highlights.
Sangamo Therapeutics, Inc., a genomic medicine company, announced that CEO Sandy Macrae will present at the 2019 Wedbush PacGrow Healthcare Conference in New York City.
Sangamo Therapeutics, Inc., a genomic medicine company, announced the appointment of Gary H. Loeb as Executive Vice President and General Counsel, effective immediately.
Sangamo Therapeutics, Inc., a genomic medicine company, announced that the Company will release its second quarter 2019 financial results after the market closes on Wednesday, August 7, 2019.
Sangamo Announces Nature Biotechnology Publication of New Strategies for Optimizing the Specificity of Gene Editing Nucleases
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the publication in Nature Biotechnology of a manuscript by Jeffrey Miller, Ph.D., and colleagues at Sangamo, describing two new strategies for optimizing the specificity of genome editing using zinc finger nucleases (ZFNs)
Sangamo and Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels
Sangamo Therapeutics, Inc. and Pfizer, Inc. announced updated results from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A.
Sangamo Therapeutics Announces Nature Medicine Publication Detailing the Activity of Disease Allele-Selective Zinc Finger Proteins in Preclinical Models of Huntington’s Disease
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the publication of a manuscript describing the activity of allele-selective zinc finger protein transcription-factors (ZFP-TFs) in preclinical models of Huntington’s disease (HD).
Sangamo Announces Upcoming Presentation Of Investigational SB-525 Hemophilia A Gene Therapy Data At ISTH 2019
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced the upcoming presentation of data from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy in patients with severe hemophilia A
Andrew Douthwaite, chief technology officer for Colorado-based VirtualArmour, a cybersecurity company, told BioSpace that biotech and pharma companies are desirable targets for hackers and cyber thieves due to the value of the intellectual property.
Sangamo Therapeutics Announces Presentations At Upcoming Scientific, Medical And Investor Conferences
Hemophilia A SB-525 gene therapy clinical data accepted for oral presentation at ISTH
Sangamo Therapeutics Announces Participation In The Bank Of America Merrill Lynch 2019 Health Care Conference
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced today that Sangamo will participate in the Bank of America Merrill Lynch 2019 Health Care Conference being held next week in Las Vegas
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported first quarter 2019 financial results and recent business highlights.
Sangamo Therapeutics, Inc. announced that the Company will release its first quarter 2019 financial results after the market closes on Wednesday, May 8, 2019.
Sangamo Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares - April 8, 2019
Sangamo Therapeutics, Inc. announced the completion of its previously announced underwritten public offering of 12,650,000 shares of its common stock at a price to the public of $11.50 per share, including 1,650,000 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $11.50 per share.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced that it has commenced an underwritten public offering of shares of its common stock.
The California-based company also shared positive early data from a beta thalassemia study and announced plans to increase AAV manufacturing.
Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data
Conference call and webcast scheduled for 8:00 a.m. Eastern Time
Sangamo Announces Agreement Securing Access To Large-Scale, Commercial-Grade Manufacturing Capacity At Brammer Bio
Balanced in-house and contract manufacturing strategy to provide clinical and commercial supply for Sangamo's growing pipeline of AAV-based genomic therapies
Eight patients treated with SB-525 gene therapy showed dose-dependent increases in FVIII activity, with the two patients treated with the 3e13 vg/kg dose reaching normal FVIII levels